参芪扶心口服液对心肌梗塞后慢性心功能不全患者血浆利钾尿肽与左心室重塑的影响

Effects of Shenqi Fuxin Oral Liquid on Plasma Kaliuretic Peptide and Left Ventricular Repiasticity in the Patient of Chronic Cardiac Functional Insufficiency after Myocardiac Infarction

目的:观察参芪扶心口服液对心肌梗塞后慢性心功能不全患者血浆利钾尿肽(KP)、心功能及左室重塑的影响。方法:将80例心肌梗塞后慢性心功能不全患者随机分为治疗组(44例)和对照组(36例),两组患者常规治疗相同,治疗组加用参芪扶心口服液,对照组加用卡托普利,两组治疗前后采用放血法检测血浆KP、内皮素-1(ET-1)及心钠素(ANP),于6个月后运用超声心动图观察心脏重塑和心功能的变化。结果:治疗组总有效率86.1％,对照组总有效率90.3％,两组比较差异无统计学意义(P>0.05);两组治疗后心脏重塑和心功能指标与治疗前比较均有显著改善(P<0.01),且ANP、ET-1与治疗前相比均明显降低(P<0.05或P<0.01)。治疗组治疗后KP较治疗前明显下降(P<0.05),而对照组无明显变化(P>0.05)。结论;参芪扶心口服液能降低心肌梗塞后慢性心功能不全患者血浆KP水平,具有阻止心脏重塑、改善心功能的作用。

Objective: Go observe effects of Shenqi Fuxin Oral Liquid on plasma kaliuritic peptide (KP) . cardiac function and left ventricular replastisity. Methods: 80 cases of chronic cardiac functional insufficiency after myocardial infarction were randomly divided into treatment group (n = 44) and control group (n = 36). Both groups were given the same routine treatment, and the treatment group was added with Shenqi Fuxin Oral Liquid and the control group with Captopril. Plasma K.P, endothelin-1 (ET-1) and atrial natriuretic polypeptide (ANP) before and after treatment were determined, and 6 months later, changes of the left ventricular replastisity and cardiac function were investigated by color ultrasound cardiogram. Results: Total effective rate was 86. 1% in the treatment group and 90. 3% in the control group with no significant difference between two groups (P > 0. 05). After treatment the indexes of the cardiac replasticity and cardiac function in both groups improved significantly (P<0. 01) . and ANP and ET-1 levels significantly decreased as compared with those before treatment GP<0. 01 or P<0. 05). After treatment, KP level in the treatment group decreased significantly as compared with that before treatment (P<0. 05), and in the control group it did not change significantly (P > 0.05). Conclusion: Shenqi Fuxin Oral Liquid can decrease plasma KP level and has functions of arresting cardiac replasticity, improving cardiac function in the patient of chronic cardiac functional insufficiency after myocardial infarction.